The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the anxieties attached to this emerging technology, with the phenomenon of hallucinations driving several calls for more stringent regulation of this class of products that might be applied toward other entries in the class of artificial intelligence.

On the heels of U.S. FDA approval for Neurophet Aqua, an updated version of its artificial intelligence (AI)-based magnetic resonance imaging analysis software for the brain, Neurophet Inc. is preparing for an IPO in 2025 and expansion into U.S. and European markets.

A new position paper from the International Society of Hypertension pinpoints the benefits and drawbacks of novel blood pressure management technology, including the latest cuff-based and cuffless and wearable devices like BP-measuring watches and rings.

Nevro Corp. received CE mark certification for its HFX iQ spinal cord stimulation system that delivers pain relief.

South Korean researchers developed a novel quantum dot and parallel-stacked organic light-emitting diode (QD-PSOLED)-based wearable patch capable of being “freely tunable” in real-time, and described as a flexible and commercial-level technology with wide applications for health care wearables.

For Inocras Inc., the benefits of whole genome sequencing are two-fold. First is its explicit usefulness in diagnosing and treating hard-to-treat diseases like cancer and rare diseases. The second, less apparent, benefit lies in the data generated in the process, and its applications to current and future generations of cancer patients.

Mobile health platform company Helfie AI has partnered with Microsoft to offer Microsoft enterprise customers the ability to license Helfie’s cutting-edge health assessment tools directly through the Microsoft Azure Marketplace.

Children with autism spectrum disorder (ASD) often must wait years before they get a diagnosis, and that wait time can result in missed opportunities for changing behaviors associated with autism.

A recent retrospective cohort study of Insight MMG highlighted potential of Lunit Inc.’s artificial intelligence-powered breast cancer screening tool in detecting “subtle signs of cancer” earlier for women.

The first patenting from Neuro-Joy Ltd. details development of a device that electrically stimulates facial nerves and muscles in order to emulate a facial expression configured to ameliorate a mood disorder and improve symptoms of depression, anxiety and sleep disorders.